Roles
Professor of Medicine, Microbiology & Immunology
William J. Harrington Chair in Hematology
-
Biography
Joseph Rosenblatt, M.D., Professor of Medicine Division of Hematology and SCCC Associate Director for Faculty Development, is a physician scientist with a long track record of clinically relevant translational research and experience in mentoring young researchers. Dr. Rosenblatt has been the institutional PI on the ACS IRG since 2006. Dr. Rosenblatt has over 25 years of experience as a Division Chief in Hematology/Oncology at two separate institutions (University of Rochester 1995 – 2001, University of Miami, 2001 –2021). Dr. Rosenblatt served as Division Chief of a combined Division of Hematology-Oncology at UM from 2001-2017, and continued to serve as Division Chief in Hematology, until stepping down to focus on translational research and education January 1, 2021.
Dr Rosenblatt has an active clinical practice focused on patients with lymphoid malignancies.
Dr. Rosenblatt received an NHLBI Physician Scientist award, NIH Shannon Award, LLS, multiple NCI R01 awards, DOD awards , has participated as a PI in several NCI Program Projects related to Gene Therapy, at UCLA , and Viral Oncology and Tumor Immunology at the University of Miami or human retroviral (HTLV-I/II), gene therapy and immunotherapy related research since 1986. He served as standing member of the NCI Experimental Therapeutics II (ET-2), Clinical Immunology and Immunotherapy II (C-II), VA Hematology and DOD study sections including an NCI Special Emphasis Panel for SPORE reviews, and served as a member of the Israel Cancer Research Fund Scientific Review Panel. He served as a member of the AACR Minority Council and was international co-organizer of an AACR meeting in Jerusalem, Israel on Translational Cancer Research. Dr. Rosenblatt has been the institutional PI on the ACS Institutional Research grant since 2006. Rosenblatt is also the PI for the American Cancer Society (ACS) Diversity in Cancer Research (DICR) Internship Program which provides a structured mentored research experience for underrepresented minorities in cancer research.
Numerous trainees of Dr. Rosenblatt’s fellowship programs and or laboratory have pursued academic or industrial research careers including faculty and research positions as well as key industrial research positions .Rosenblatt served on the SCCC Scientific Steering Committee, as SCCC Associate Director for Faculty Development since 2012, and on the SCCC Cancer Education Leadership Council (CELC). Dr. Rosenblatt has also received multiple awards including the BARKIN/Rogers Mentoring Award from the UM Department of Medicine in 2017 and the SCCC Mentoring Award in 2021. -
Education & Training
Education
Post Graduate Training
-
Research Interests
The Rosenblatt laboratory has engaged in development of novel antibody-based bi-functional molecules with the ability to promote an enhanced anti-angiogenic response, or to enhance a local anti- tumor immune response. Many of these molecules represented totally unique approaches including development of antibody fusions directed against the HER2 tyrosine kinase expressed on a subset of breast, ovarian and other solid tumors, as well as more recent anti-EGFR directed fusion proteins in triple negative breast cancer . Many of these have had unique conceptual and biologic activities such as ability to deliver a costimulatory ligand by antibody (B7.1 fusion), chemotactic stimulus through coupling of a chemokine, or local delivery of an anti-angiogenic peptide, which markedly enhances the anti- tumor efficacy of endostatin and uniquely inhibits angiogenesis, vessel co-option, and vasculogenic mimicry by solid tumors , as well as lymphoid malignancies.
The Rosenblatt lab was a pioneer in the early development of novel gene therapy-based approaches designed to augment anti-tumor immune response. These contributions include the development of HSV based amplicon vectors in collaboration, the combined use of chemokine and costimulatory ligand delivery to augment response, and demonstration of the ability to enhance immunogenicity of hematologic malignancies such as CLL using HSV amplicons
The Rosenblatt laboratory was also among the first to demonstrate the potential immune suppressive effects of B regulatory cells in solid tumor models including EL-4 thymoma, MC-38 colon cancer, and EMT- 6 mammary carcinoma.
he role of B regulatory cells in solid tumor immune suppression is now increasingly appreciated and accepted.. These observations laid a conceptual foundation for similar observations in triple negative breast cancer, , and other solid tumors
the Rosenblatt also made numerous contributions to understanding of the molecular biology of. HTLV-I, HTLV-II and d pathogenesis of HTLV-1 in relation to adult. T cell leukemia-lymphoma as well as HTLV-1associated myelopathy -
Publications
Disclaimer: The information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, please use this link to inform our data team. Your feedback is greatly appreciated and helps us improve the quality of our content.